



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2019	2018	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾					
BABY CARE					
US	\$ 87	\$ 97	-10.9%	-10.9%	-
Intl	307	360	-14.8%	-6.4%	-8.4%
WW	394	457	-14.0%	-7.4%	-6.6%
BEAUTY					
US	588	611	-3.8%	-3.8%	-
Intl	502	473	6.2%	13.1%	-6.9%
WW	1,090	1,084	0.6%	3.6%	-3.0%
ORAL CARE					
US	151	157	-3.5%	-3.5%	-
Intl	216	222	-2.8%	4.6%	-7.4%
WW	367	379	-3.1%	1.2%	-4.3%
OTC					
US	507	465	9.1%	9.1%	-
Intl	580	607	-4.6%	2.8%	-7.4%
WW	1,087	1,072	1.3%	5.5%	-4.2%
WOMEN'S HEALTH					
US	3	3	4.2%	4.2%	-
Intl	222	240	-7.5%	4.3%	-11.8%
WW	225	243	-7.3%	4.3%	-11.6%
WOUND CARE / OTHER					
US	102	103	-0.9%	-0.9%	-
Intl	53	60	-11.6%	-6.0%	-5.6%
WW	155	163	-4.8%	-2.7%	-2.1%
TOTAL CONSUMER					
US	1,438	1,436	0.2%	0.2%	-
Intl	1,880	1,962	-4.2%	3.7%	-7.9%
WW	\$ 3,318	\$ 3,398	-2.4%	2.2%	-4.6%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

PHARMACEUTICAL SEGMENT ⁽²⁾⁽⁴⁾

IMMUNOLOGY

	2019		2018		% Change		
	2019	2018	Reported	Operational ⁽¹⁾	Currency		
US	\$ 2,163	\$ 2,000	8.1%	8.1%	-		
Intl	1,088	1,042	4.5%	12.6%	-8.1%		
WW	3,251	3,042	6.9%	9.6%	-2.7%		

REMICADE

US	774	916	-15.5%	-15.5%	-		
US Exports ⁽³⁾	76	142	-46.4%	-46.4%	-		
Intl	252	331	-23.6%	-17.2%	-6.4%		
WW	1,102	1,389	-20.6%	-19.1%	-1.5%		

SIMPONI / SIMPONI ARIA

US	263	224	17.0%	17.0%	-		
Intl	261	294	-11.1%	-3.8%	-7.3%		
WW	524	518	1.0%	5.2%	-4.2%		

STELARA

US	882	652	35.2%	35.2%	-		
Intl	523	409	27.9%	37.2%	-9.3%		
WW	1,405	1,061	32.4%	36.0%	-3.6%		

TREMFYA

US	168	66	*	*	-		
Intl	49	6	*	*	*		
WW	217	72	*	*	*		

OTHER IMMUNOLOGY⁽⁴⁾

US	-	-	-	-	-		
Intl	3	2	19.5%	21.0%	-1.5%		
WW	3	2	19.5%	21.0%	-1.5%		

INFECTIOUS DISEASES

US	357	333	7.3%	7.3%	-		
Intl	489	497	-1.7%	7.8%	-9.5%		
WW	846	830	1.9%	7.6%	-5.7%		

EDURANT / rilpivirine

US	12	14	-18.8%	-18.8%	-		
Intl	199	196	2.2%	10.6%	-8.4%		
WW	211	210	0.8%	8.6%	-7.8%		

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US	315	273	15.5%	15.5%	-		
Intl	208	205	1.5%	11.9%	-10.4%		
WW	523	478	9.5%	13.9%	-4.4%		

OTHER INFECTIOUS DISEASES

US	30	46	-33.8%	-33.8%	-		
Intl	82	96	-16.0%	-6.3%	-9.7%		
WW	112	142	-21.7%	-15.1%	-6.6%		

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2019	2018	% Change		
			Reported	Operational ⁽¹⁾	Currency
NEUROSCIENCE					
US	723	624	16.0%	16.0%	-
Intl	905	935	-3.2%	4.3%	-7.5%
WW	1,629	1,559	4.5%	9.0%	-4.5%
<u>CONCERTA / methlyphenidate</u>					
US	97	66	47.7%	47.7%	-
Intl	116	107	8.5%	15.8%	-7.3%
WW	214	173	23.4%	28.0%	-4.6%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	483	400	20.7%	20.7%	-
Intl	307	296	3.8%	12.3%	-8.5%
WW	790	696	13.5%	17.1%	-3.6%
<u>RISPERDAL CONSTA</u>					
US	77	82	-6.8%	-6.8%	-
Intl	102	114	-10.3%	-2.4%	-7.9%
WW	179	196	-8.8%	-4.3%	-4.5%
<u>OTHER NEUROSCIENCE</u>					
US	66	76	-12.0%	-12.0%	-
Intl	379	418	-9.2%	-2.5%	-6.7%
WW	446	494	-9.6%	-3.9%	-5.7%
ONCOLOGY					
US	962	933	3.1%	3.1%	-
Intl	1,556	1,378	13.0%	22.2%	-9.2%
WW	2,518	2,311	9.0%	14.5%	-5.5%
<u>DARZALEX</u>					
US	352	264	33.0%	33.0%	-
Intl	277	168	65.1%	80.1%	-15.0%
WW	629	432	45.5%	51.3%	-5.8%
<u>IMBRUVICA</u>					
US	349	227	53.7%	53.7%	-
Intl	435	360	20.8%	32.0%	-11.2%
WW	784	587	33.5%	40.4%	-6.9%
<u>VELCADE</u>					
US	-	-	-	-	-
Intl	263	313	-16.0%	-10.1%	-5.9%
WW	263	313	-16.0%	-10.1%	-5.9%
<u>ZYTIGA / Abiraterone Acetate</u>					
US	185	407	-54.5%	-54.5%	-
Intl	494	438	12.9%	20.9%	-8.0%
WW	679	845	-19.6%	-15.4%	-4.2%
<u>OTHER ONCOLOGY</u>					
US	76	35	*	*	-
Intl	87	99	-12.2%	-3.9%	-8.3%
WW	163	134	21.7%	27.8%	-6.1%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2019	2018	% Change		
			Reported	Operational ⁽¹⁾	Currency
<u>PULMONARY HYPERTENSION</u>					
US	430	361	19.2%	19.2%	-
Intl	226	224	0.7%	8.6%	-7.9%
WW	<u>656</u>	<u>585</u>	12.1%	15.1%	-3.0%
<u>OPSUMIT</u>					
US	172	149	15.9%	15.9%	-
Intl	133	122	8.9%	17.8%	-8.9%
WW	<u>306</u>	<u>271</u>	12.7%	16.8%	-4.1%
<u>TRACLEER</u>					
US	61	68	-10.1%	-10.1%	-
Intl	56	72	-22.9%	-18.3%	-4.6%
WW	<u>117</u>	<u>140</u>	-16.7%	-14.4%	-2.3%
<u>UPTRAVI</u>					
US	176	124	41.4%	41.4%	-
Intl	22	16	42.8%	53.6%	-10.8%
WW	<u>198</u>	<u>140</u>	41.6%	42.8%	-1.2%
<u>OTHER</u>					
US	21	20	3.6%	3.6%	-
Intl	15	14	4.6%	17.1%	-12.5%
WW	<u>35</u>	<u>34</u>	4.0%	9.2%	-5.2%
<u>CARDIOVASCULAR / METABOLISM / OTHER</u>					
US	947	1,103	-14.1%	-14.1%	-
Intl	398	414	-3.9%	2.7%	-6.6%
WW	<u>1,345</u>	<u>1,517</u>	-11.3%	-9.5%	-1.8%
<u>XARELTO</u>					
US	542	578	-6.3%	-6.3%	-
Intl	-	-	-	-	-
WW	<u>542</u>	<u>578</u>	-6.3%	-6.3%	-
<u>INVOKANA / INVOKAMET</u>					
US	154	204	-24.8%	-24.8%	-
Intl	49	44	11.6%	20.0%	-8.4%
WW	<u>202</u>	<u>248</u>	-18.4%	-16.9%	-1.5%
<u>PROCRIT / EPREX</u>					
US	148	189	-21.6%	-21.6%	-
Intl	78	87	-10.2%	-5.2%	-5.0%
WW	<u>226</u>	<u>276</u>	-18.0%	-16.4%	-1.6%
<u>OTHER</u>					
US	104	132	-21.3%	-21.3%	-
Intl	271	283	-4.4%	2.5%	-6.9%
WW	<u>374</u>	<u>415</u>	-9.7%	-5.1%	-4.6%
<u>TOTAL PHARMACEUTICAL</u>					
US	5,582	5,354	4.3%	4.3%	-
Intl	4,662	4,490	3.9%	12.2%	-8.3%
WW	<u>\$ 10,244</u>	<u>\$ 9,844</u>	4.1%	7.9%	-3.8%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

MEDICAL DEVICES SEGMENT ⁽²⁾⁽⁵⁾

DIABETES CARE⁽⁵⁾

US
Intl
WW

INTERVENTIONAL SOLUTIONS

US
Intl
WW

ORTHOPAEDICS

US
Intl
WW

HIPS

US
Intl
WW

KNEES

US
Intl
WW

TRAUMA

US
Intl
WW

SPINE & OTHER

US
Intl
WW

		FIRST QUARTER			
			% Change		
	<u>2019</u>	<u>2018</u>	<u>Reported</u>	<u>Operational</u> ⁽¹⁾	<u>Currency</u>
	\$ -	\$ 117	*	*	-
	-	222	*	*	*
	-	339	*	*	*
	343	304	12.6%	12.6%	-
	389	336	15.8%	22.7%	-6.9%
	732	640	14.3%	17.9%	-3.6%
	1,318	1,307	0.9%	0.9%	-
	885	943	-6.2%	0.7%	-6.9%
	2,204	2,250	-2.1%	0.8%	-2.9%
	213	209	2.1%	2.1%	-
	148	154	-3.8%	3.5%	-7.3%
	361	363	-0.4%	2.7%	-3.1%
	223	228	-2.2%	-2.2%	-
	146	159	-8.2%	-1.5%	-6.7%
	369	387	-4.7%	-1.9%	-2.8%
	417	407	2.5%	2.5%	-
	268	289	-7.0%	-0.3%	-6.7%
	685	696	-1.4%	1.3%	-2.7%
	465	463	0.3%	0.3%	-
	323	341	-5.5%	1.3%	-6.8%
	788	804	-2.2%	0.7%	-2.9%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2019	2018	% Change		
			Reported	Operational ⁽¹⁾	Currency
<u>SURGERY</u>					
US	1,001	993	0.8%	0.8%	-
Intl	1,394	1,430	-2.6%	4.7%	-7.3%
WW	2,395	2,423	-1.2%	3.1%	-4.3%
<u>ADVANCED</u>					
US	404	393	2.9%	2.9%	-
Intl	576	573	0.5%	7.7%	-7.2%
WW	980	966	1.5%	5.8%	-4.3%
<u>GENERAL</u>					
US	425	423	0.3%	0.3%	-
Intl	665	704	-5.6%	1.6%	-7.2%
WW	1,089	1,127	-3.4%	1.1%	-4.5%
<u>SPECIALTY</u>					
US	172	177	-2.5%	-2.5%	-
Intl	153	153	-0.2%	7.6%	-7.8%
WW	325	330	-1.4%	2.2%	-3.6%
<u>VISION</u>					
US	446	440	1.5%	1.5%	-
Intl	682	675	1.1%	7.2%	-6.1%
WW	1,129	1,115	1.2%	5.0%	-3.8%
<u>CONTACT LENSES / OTHER</u>					
US	321	309	4.1%	4.1%	-
Intl	502	498	1.0%	7.4%	-6.4%
WW	824	807	2.1%	6.1%	-4.0%
<u>SURGICAL</u>					
US	125	131	-4.5%	-4.5%	-
Intl	180	177	1.3%	6.8%	-5.5%
WW	305	308	-1.1%	2.0%	-3.1%
<u>TOTAL MEDICAL DEVICES</u>					
US	3,109	3,161	-1.6%	-1.6%	-
Intl	3,350	3,606	-7.1%	-0.3%	-6.8%
WW	\$ 6,459	\$ 6,767	-4.6%	-1.0%	-3.6%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Reported as U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure

(5) Reflects LifeScan divestiture October 2, 2018